These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9090973)

  • 1. Residual androgen depending in hormone-resistant prostate cancer.
    Fosså SD
    Acta Oncol; 1997; 36(1):81-2. PubMed ID: 9090973
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
    Krongrad A; Brady J; Rodriguez RJ
    South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases.
    Fontana D; Bertetto O; Fasolis G; Berruti A; Tarabuzzi R; Pagani G; Buniva T; Zolfanelli R; Pallotti S; Frezzotti L; Bumma C; Rossetti SR; Dogliotti L
    Tumori; 1998; 84(1):39-44. PubMed ID: 9619712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
    Furuya Y; Nozaki T; Nagakawa O; Fuse H
    Endocr J; 2002 Feb; 49(1):85-90. PubMed ID: 12008754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we follow-up serum testosterone in patients with advanced prostate cancer?
    Perachino M
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1031-5. PubMed ID: 20645692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T
    Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Managing side effects of androgene deprivation in prostate cancer].
    Thalgott M; Gschwend JE; Retz M
    MMW Fortschr Med; 2010 Oct; 152(41):40-3. PubMed ID: 21090376
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
    Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
    Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.
    Sasagawa I; Nakada T; Kubota Y; Sawamura T; Izumiya K
    Int Urol Nephrol; 1995; 27(6):769-74. PubMed ID: 8725045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of first-line treatment for metastatic prostate cancer.
    Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
    Bolla M; de Reijke TM; Zurlo A; Collette L
    Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
    [No Abstract]   [Full Text] [Related]  

  • 12. [Quality of life of patients with prostatic cancer under hormonal therapy].
    Aliaev IuG; Aslamazov EG; Demidko IuL
    Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy.
    Soloway MS
    Prog Clin Biol Res; 1990; 350():141-8. PubMed ID: 2201040
    [No Abstract]   [Full Text] [Related]  

  • 14. [PSA progression under hormone therapy - of prognostic relevance?].
    Miller K
    Aktuelle Urol; 2012 Jul; 43(4):262-4. PubMed ID: 22869497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy.
    Olapade-Olaopa EO; Oluwasola AO; Shonibare A; Falebita OA; Akang EE; Shokunbi MT
    S Afr Med J; 2006 Sep; 96(9):810-1. PubMed ID: 17068650
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
    Kreis W; Budman DR; Delli Bovi P; Vinciguerra V
    Onkologie; 1988 Dec; 11(6):292-3. PubMed ID: 2977219
    [No Abstract]   [Full Text] [Related]  

  • 17. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 18. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
    Bankhead C
    J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
    [No Abstract]   [Full Text] [Related]  

  • 20. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.